Dinaciclib exerts a tumor-suppressing effect via β-catenin/YAP axis in pancreatic ductal adenocarcinoma

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Fusobacterium nucleatum Promotes the Progression of Colorectal Cancer Through Cdk5-Activated Wnt/β-Catenin Signaling

(2021) Xiang Li et al.   Frontiers in Microbiology

OTUD5-mediated deubiquitination of YAP in macrophage promotes M2 phenotype polarization and favors triple-negative breast cancer progression

(2021) Yujiao Zhang et al.   CANCER LETTERS

Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ

(2021) Hyeryun Kwon et al.   FEBS Journal

CDK5 activates Hippo signaling to confer resistance to radiotherapy via upregulating TAZ in lung cancer

(2020) Yulan Zeng et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer

(2020) Adrian G. Murphy et al.   CTS-Clinical and Translational Science

Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells

(2019) Paul Dent et al.   ONCOGENE

YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine

(2019) Ling Zhou et al.   Biomolecules

Dinaciclib induces immunogenic cell death and enhances anti-PD1–mediated tumor suppression

(2018) Dewan Md Sakib Hossain et al.   JOURNAL OF CLINICAL INVESTIGATION

Inhibition of Cyclin-dependent Kinase 5 - a Novel Strategy to Improve Sorafenib Response in HCC Therapy

(2018) Maximilian A. Ardelt et al.   HEPATOLOGY

The Hippo Pathway: Biology and Pathophysiology

(2018) Shenghong Ma et al.   Annual Review of Biochemistry

Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer

(2018) Yumeng Wang et al.   Cell Reports

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ

(2017) A Noto et al.   ONCOGENE

Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis

(2017) Maria Teresa Salcedo Allende et al.   PANCREAS

A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer

(2017) Shu-Fu Lin et al.   PLoS One

YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine

(2016) Zhengdong Jiang et al.   Nutrients

Low Expression of CDK5 and p27 Are Associated with Poor Prognosis in Patients with Gastric Cancer

(2016) Yu-Qin Sun et al.   Journal of Cancer

Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its Nuclear Accumulation Suppresses Gastric Tumorigenesis

(2015) L. Cao et al.   CLINICAL CANCER RESEARCH

Structural basis for Mob1-dependent activation of the core Mst–Lats kinase cascade in Hippo signaling

(2015) Lisheng Ni et al.   GENES & DEVELOPMENT

YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells

(2015) YANLI YUAN et al.   Molecular Medicine Reports

Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3

(2015) Shuping Yang et al.   Oncotarget

Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma

(2014) W. Zhang et al.   Science Signaling

Wnt/β-Catenin Signaling Regulates Yes-associated Protein (YAP) Gene Expression in Colorectal Carcinoma Cells

(2012) Wesley M. Konsavage et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells

(2012) Caroline H. Diep et al.   PLoS One

Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis

(2011) W. Kang et al.   CLINICAL CANCER RESEARCH

Cyclin-Dependent Kinase 5 Is Amplified and Overexpressed in Pancreatic Cancer and Activated by Mutant K-Ras

(2011) J. P. Eggers et al.   CLINICAL CANCER RESEARCH

Pancreatic cancer

(2011) Audrey Vincent et al.   LANCET

Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene

(2010) C. A. Hall et al.   CANCER RESEARCH

Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer

(2010) Yang Wang et al.   CANCER SCIENCE

YAP is a candidate oncogene for esophageal squamous cell carcinoma

(2010) Tomoki Muramatsu et al.   CARCINOGENESIS

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF -TRCP

(2010) B. Zhao et al.   GENES & DEVELOPMENT

The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCPE3 Ligase

(2010) Chen-Ying Liu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

(2010) David Parry et al.   MOLECULAR CANCER THERAPEUTICS

The TEAD/TEF Family of Transcription Factor Scalloped Mediates Hippo Signaling in Organ Size Control

(2008) Lei Zhang et al.   DEVELOPMENTAL CELL

TEAD mediates YAP-dependent gene induction and growth control

(2008) B. Zhao et al.   GENES & DEVELOPMENT